title: Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter.
abstract: Feline Immnunodeficiency (FIV) and Feline Leukemia (FeLV) viruses are common infectious agents in stray cats and shelter environments. Recombinant feline interferon-ω (rFeIFNω) has shown an antiviral action not only against FIV and FeLV but also against herpesvirus (FHV-1) and calicivirus (FCV). Sixteen naturally infected FIV/FeLV cats were followed during rFeIFNω therapy in order to monitor clinical signs and to correlate with excretion of concomitant viruses (FCV, FHV-1, feline coronavirus (FCoV) and parvovirus (FPV)). Cats were submitted to clinical evaluations and concomitant virus excretion assessement. Comparing D0-D65, 10/16 cats improved clinical scores. Of the 10 cats positive for FHV-1 on D0, 4 were negative and 6 reduced viral loads. Of the 11 FCoV positive cats, 9 reduced viral loads. The 13 FCV positive cats and the FPV positive cat were negative on D65. In conclusion, rFeIFNω improves clinical signs and reduces concurrent viral excretion in naturally infected retroviral cats.
authors.affiliation: Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, Technical University of Lisbon (TULisbon), Av. Universidade Técnica, 1300-477 Lisbon, Portugal. solange@fmv.utl.pt
authors.forename: Solange
authors.initials: S
authors.lastname: Gil
authors.forename: Rodolfo O
authors.initials: RO
authors.lastname: Leal
authors.forename: Ana
authors.initials: A
authors.lastname: Duarte
authors.forename: David
authors.initials: D
authors.lastname: McGahie
authors.forename: Nuno
authors.initials: N
authors.lastname: Sepúlveda
authors.forename: Inês
authors.initials: I
authors.lastname: Siborro
authors.forename: Joana
authors.initials: J
authors.lastname: Cravo
authors.forename: Clara
authors.initials: C
authors.lastname: Cartaxeiro
authors.forename: Luís M
authors.initials: LM
authors.lastname: Tavares
mesh_terms: D000818:Animals; D002415:Cats; D060085:Coinfection / Q000188:drug therapy / Q000662:veterinary / Q000821:virology; D016765:Coronavirus, Feline / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D016181:Feline Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D016766:Feline Infectious Peritonitis / Q000150:complications / Q000188:drug therapy; D005254:Feline Panleukopenia / Q000150:complications / Q000188:drug therapy; D028301:Feline Panleukopenia Virus / Q000187:drug effects; D005260:Female; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects; D007370:Interferon Type I / Q000627:therapeutic use*; D005256:Leukemia Virus, Feline / Q000187:drug effects; D016582:Leukemia, Feline / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; C063743:interferon omega 1